Palmitoyl Tetrapeptide-7
Also known as: Pal-GQPR, Rigin, Part of Matrixyl 3000
Palmitoyl Tetrapeptide-7 (also called Pal-GQPR or Rigin) is a cosmetic matrikine in the Matrix / Angiogenic class. Palmitoyl tetrapeptide-7 is a short peptide with a palmitoyl chain added for skin penetration, used topically for its reported effect on cutaneous inflammatory signalling.
For research use only.
Key Facts
- CAS
- 221227-05-0
- Molecular Weight (MW)
- ≈694.9 g/mol
- Half-life
- Topical; systemic PK not established
- FDA status
- Not Approved
- Administration Route
- Topical
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- IL-6 / dermal inflammation (cosmetic models)
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Dec 2025, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 1
- Listed offers
- 1
- Price per mg
- $0.900/mg
Research summary
Palmitoylated GQPR tetrapeptide used to reduce IL-6 in stressed skin models and paired with pal-tripeptide-1 in Matrixyl 3000.
Peptide Library's Palmitoyl Tetrapeptide-7 profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Per cosmetic formulation
- Frequency
- —
- Cycle
- —
- Administration Route
- Topical
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Palmitoyl Tetrapeptide-7 is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C34H62N8O7 |
|---|---|
| Molecular weight | ≈694.9 g/mol |
| CAS number | 221227-05-0 |
| Half-life | Topical; systemic PK not established |
| Appearance | White powder |
| Formulation | Topical Cream |
| PubChem CID | 10078408 |
| FDA UNII | Q41S464P1R |
| DrugBank | DB14137 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Palmitoyl tetrapeptide-7 is a short peptide with a palmitoyl chain added for skin penetration, used topically for its reported effect on cutaneous inflammatory signalling. Supplier and cosmetic studies describe reduced production of interleukin-6 by keratinocytes and fibroblasts after ultraviolet or inflammatory challenge. The rationale is that chronic low-grade inflammation contributes to matrix degradation in photoaged skin, so damping cytokine output is intended to slow that process rather than to stimulate collagen directly. It is most often formulated alongside palmitoyl pentapeptide-4, which acts on matrix synthesis, and most published data concerns the combination rather than the isolated ingredient.
Origin
Synthetic palmitoylated tetrapeptide.
Targets
Studies
- Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream
- Usage of Synthetic Peptides in Cosmetics for Sensitive Skin
- Injectable polypeptide/chitosan hydrogel with loaded stem cells and rapid gelation promoting angiogenesis for diabetic wound healing
- Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using matrix-assisted laser desorption/ionization mass spectrometric imaging, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications
Regulatory & research status
Palmitoyl Tetrapeptide-7 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | OTC / Supplement |
| WADA (sport) | Permitted |
| Library classification | Research-Only |
Benefits
Palmitoyl Tetrapeptide-7 side effects
Side Effects
- Irritation uncommon
Stacking
Common stacking partners
Combinations that include Palmitoyl Tetrapeptide-7, with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Cosmetic peptides in this library are formulated into topical products; follow the product label rather than the reconstitution guidance above.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Palmitoyl Tetrapeptide-7: frequently asked questions
What is Palmitoyl Tetrapeptide-7?
Palmitoylated GQPR tetrapeptide used to reduce IL-6 in stressed skin models and paired with pal-tripeptide-1 in Matrixyl 3000.
How does Palmitoyl Tetrapeptide-7 work?
Palmitoyl tetrapeptide-7 is a short peptide with a palmitoyl chain added for skin penetration, used topically for its reported effect on cutaneous inflammatory signalling. Supplier and cosmetic studies describe reduced production of interleukin-6 by keratinocytes and fibroblasts after ultraviolet or inflammatory challenge.
Is Palmitoyl Tetrapeptide-7 FDA approved?
No. Palmitoyl Tetrapeptide-7 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Palmitoyl Tetrapeptide-7?
Reported half-life for Palmitoyl Tetrapeptide-7 is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Palmitoyl Tetrapeptide-7 banned in sport?
Palmitoyl Tetrapeptide-7 is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Palmitoyl Tetrapeptide-7?
Compounds most often compared with Palmitoyl Tetrapeptide-7 include Palmitoyl Pentapeptide-4, Palmitoyl Tripeptide-5, Acetyl Hexapeptide-8 and Acetyl Octapeptide-3. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- PubChem Pal-GQPRExternal reference
- Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream — Skin Res Technol, 2024External reference
- Usage of Synthetic Peptides in Cosmetics for Sensitive Skin — Pharmaceuticals (Basel), 2021External reference
- Injectable polypeptide/chitosan hydrogel with loaded stem cells and rapid gelation promoting angiogenesis for diabetic wound healing — Int J Biol Macromol, 2025External reference
- Evaluation of dermal extracellular matrix and epidermal-dermal junction modifications using matrix-assisted laser desorption/ionization mass spectrometric imaging, in vivo reflectance confocal microscopy, echography, and histology: effect of age and peptide applications — J Cosmet Dermatol, 2015External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Palmitoyl Tetrapeptide-7 profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Palmitoyl Tetrapeptide-7 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →